Skip to main content
. Author manuscript; available in PMC: 2018 Apr 24.
Published in final edited form as: Allergy. 2017 Jan 4;72(4):519–533. doi: 10.1111/all.13083

Figure 1.

Figure 1

Time course of known cellular and clinical effects of omalizumab identified in studies focused on (A) patients with allergic response, mast cell diseases and (B) chronic urticaria. *MacGlashan et al. (2013) observed a 2.5- to 125-fold increase in basophil sensitivity after omalizumab treatment with sensitivity shifts noted at the midpoint and after 12 weeks of treatment.